TSCAN THERAPEUTICS INC (TCRX)
US89854M1018 - Common Stock
Taking everything into account, TCRX scores 3 out of 10 in our fundamental rating. TCRX was compared to 568 industry peers in the Biotechnology industry. While TCRX seems to be doing ok healthwise, there are quite some concerns on its profitability. While showing a medium growth rate, TCRX is valued expensive at the moment.
1. Profitability
1.1 Basic Checks
In the past year TCRX has reported negative net income.
TCRX had a negative operating cash flow in the past year.
In the past 5 years TCRX always reported negative net income.
In the past 5 years TCRX always reported negative operating cash flow.
1.2 Ratios
With a decent Return On Assets value of -31.98%, TCRX is doing good in the industry, outperforming 65.66% of the companies in the same industry.
TCRX has a Return On Equity of -48.59%. This is in the better half of the industry: TCRX outperforms 67.79% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -31.98% | ||
| ROE | -48.59% | ||
| ROIC | N/A |
ROA(3y)-30.63%
ROA(5y)-34.42%
ROE(3y)-52%
ROE(5y)-68.01%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
TCRX does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
TCRX does not have a ROIC to compare to the WACC, probably because it is not profitable.
TCRX has more shares outstanding than it did 1 year ago.
The debt/assets ratio for TCRX has been reduced compared to a year ago.
2.2 Solvency
TCRX has an Altman-Z score of -0.78. This is a bad value and indicates that TCRX is not financially healthy and even has some risk of bankruptcy.
With a Altman-Z score value of -0.78, TCRX perfoms like the industry average, outperforming 60.00% of the companies in the same industry.
A Debt/Equity ratio of 0.13 indicates that TCRX is not too dependend on debt financing.
TCRX's Debt to Equity ratio of 0.13 is on the low side compared to the rest of the industry. TCRX is outperformed by 66.73% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.13 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -0.78 |
ROIC/WACCN/A
WACC12.1%
2.3 Liquidity
TCRX has a Current Ratio of 9.56. This indicates that TCRX is financially healthy and has no problem in meeting its short term obligations.
With a decent Current ratio value of 9.56, TCRX is doing good in the industry, outperforming 79.82% of the companies in the same industry.
TCRX has a Quick Ratio of 9.56. This indicates that TCRX is financially healthy and has no problem in meeting its short term obligations.
TCRX's Quick ratio of 9.56 is fine compared to the rest of the industry. TCRX outperforms 80.00% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 9.56 | ||
| Quick Ratio | 9.56 |
3. Growth
3.1 Past
TCRX shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 56.91%, which is quite impressive.
Looking at the last year, TCRX shows a very negative growth in Revenue. The Revenue has decreased by -44.73% in the last year.
Measured over the past years, TCRX shows a very strong growth in Revenue. The Revenue has been growing by 168.29% on average per year.
EPS 1Y (TTM)56.91%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-4.17%
Revenue 1Y (TTM)-44.73%
Revenue growth 3Y168.29%
Revenue growth 5YN/A
Sales Q2Q%-73.01%
3.2 Future
TCRX is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 8.30% yearly.
Based on estimates for the next years, TCRX will show a very strong growth in Revenue. The Revenue will grow by 55.47% on average per year.
EPS Next Y39.8%
EPS Next 2Y16.91%
EPS Next 3Y9.76%
EPS Next 5Y8.3%
Revenue Next Year-79.76%
Revenue Next 2Y-54.1%
Revenue Next 3Y-31.81%
Revenue Next 5Y55.47%
3.3 Evolution
The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for TCRX. In the last year negative earnings were reported.
Also next year TCRX is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y16.91%
EPS Next 3Y9.76%
5. Dividend
5.1 Amount
No dividends for TCRX!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
TSCAN THERAPEUTICS INC
NASDAQ:TCRX (12/18/2024, 4:58:37 PM)
After market: 3.04 +0.14 (+4.83%)2.9
-0.07 (-2.36%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap163.88M
Analysts
Price Target
Short Float %
Short Ratio
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -31.98% | ||
| ROE | -48.59% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.03
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.13 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 9.56 | ||
| Quick Ratio | 9.56 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
High Growth Momentum
Growth
EPS 1Y (TTM)56.91%
EPS 3YN/A
EPS 5Y
EPS Q2Q%
EPS Next Y39.8%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)-44.73%
Revenue growth 3Y168.29%
Revenue growth 5Y
Sales Q2Q%
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y